ArticleInfection and immunity2002
Protection against experimental Helicobacter pylori infection after immunization with inactivated H. pylori whole-cell vaccines.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Treatment with (R)-α-methylhistamine or IL4 stimulates mucin production and decreasesVirulence · 2025Article
- Construction and evaluation of aFrontiers in immunology · 2025Article
- Oral administration of DNA alginate nanovaccine induced immune-protection against Helicobacter pylori in Balb/C mice.BMC immunology · 2024Article
- Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.Biomolecules · 2021Review
- An oral alpha-galactosylceramide adjuvantedNPJ vaccines · 2019Article
- Current state and challenges in developing oral vaccines.Advanced drug delivery reviews · 2017Review
- Vaccine against Helicobacter pylori: Inevitable approach.World journal of gastroenterology · 2016Review
- Protease-activated receptor 1 suppresses Helicobacter pylori gastritis via the inhibition of macrophage cytokine secretion and interferon regulatory factor 5.Mucosal immunology · 2015Article
- Contribution of secretory antibodies to intestinal mucosal immunity against Helicobacter pylori.Infection and immunity · 2013Article
- Anti-Helicobacter pylori Properties of GutGard™.Preventive nutrition and food science · 2013Article
- A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.Infection and immunity · 2013Article
- Localized suppression of inflammation at sites of Helicobacter pylori colonization.Infection and immunity · 2011Article
- Expression of UreB and HspA of Helicobacter pylori in silkworm pupae and identification of its immunogenicity.Molecular biology reports · 2011Article
- Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase.Infection and immunity · 2011Article
- Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach.Infection and immunity · 2010Article
- Article
- Antibody-mediated protection against infection with Helicobacter pylori in a suckling mouse model of passive immunity.Infection and immunity · 2009Article
- M-cell targeting of whole killed bacteria induces protective immunity against gastrointestinal pathogens.Infection and immunity · 2009Article
- Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.Current drug therapy · 2008Article
- HpaA is essential for Helicobacter pylori colonization in mice.Infection and immunity · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protective effect of therapeutic oral immunization with homologous and heterologous formalin-inactivated Helicobacter pylori cells given together with cholera toxin as an adjuvant was evaluated with C57BL/6 mice infected with H. pylori Sydney strain 1 (SS1). The bacteria used for immunization were strains that were either homologous or heterologous with regard to the O antigen (i.e., the Lewis antigen [Le antigen]) expressed by the lipopolysaccharide of the infecting H. pylori SS1 strain. We found that repeated oral immunization with inactivated H. pylori SS1 cells can significantly inhibit an existing infection (P < 0.001) and that the protection induced by such therapeutic immunization extends to protection against reinfection (P < 0.001). A similar level of protection was also achieved by immunization with another inactivated H. pylori strain having the same O antigen (Le antigen) as the infecting H. pylori SS1 strain. In contrast, immunization with inactivated strains expressing a heterologous O antigen, Le(x), provided less protection or no protection. Immunization with H. pylori lysate preparations, on the other hand, resulted in significant comparable protection whether the lysates were prepared from an Le(x) strain or an Le(y) strain. Postimmunization gastritis was seen in mice that were protected after vaccination but not in unimmunized or unprotected mice. In conclusion, therapeutic immunization with inactivated H. pylori whole-cell vaccines may provide strong protection both against experimental H. pylori infection and against later reinfection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.